Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)



Status:Recruiting
Conditions:Lupus, Endocrine
Therapuetic Areas:Endocrinology, Immunology / Infectious Diseases
Healthy:No
Age Range:18 - 45
Updated:1/16/2019
Start Date:September 2003
End Date:August 2019
Contact:Marta M. Guerra, MS
Email:guerram@hss.edu
Phone:212-774-7361

Use our guide to learn which trials are right for you!

The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major
clinical centers. The purpose of the study is 1) to determine whether certain proteins
(called complement split products) that can injure healthy organs can be used to predict poor
pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid
syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic
factors predict pregnancy complications in patients with aPL antibodies and/or SLE.

Thrombosis and pregnancy loss are common features of systemic lupus erythematosus (SLE),
particularly in the presence of antiphospholipid (aPL) antibodies. The in vivo mechanisms by
which aPL antibodies lead to vascular events and, specifically, to recurrent fetal loss are
largely unknown. Studies in a mouse model of antiphospholipid antibody syndrome (APS)
indicate that in vivo complement activation is necessary for fetal loss caused by aPL
antibodies. This study represents an effort to translate these research observations on the
potential role of complement activation in the pathogenesis of aPL antibody-mediated
pregnancy loss to a clinically relevant human study.

In addition, studies in humans and mice have shown 1) that the balance of circulating
angiogenic and antiangiogenic factors predicts preeclampsia and fetal growth restriction in
healthy women, 2) circulating antiangiogenic factors cause endothelial dysfunction and
abnormal placental development in animal models, and 3) complement activation leads to
elevated levels of circulating antiangiogenic factors and complement inhibition prevents
increased levels of antiangiogenic factors, placental dysfunction and fetal growth
restriction in a mouse model of APS. This study will permit testing the hypothesis that, like
in healthy women, the balance of circulating angiogenic and antiangiogenic factors predict
complications in women with SLE and APS and to translate the findings in animal models into
humans.

The PROMISSE Study is a prospective observational study that will follow 700 pregnant
patients who will be grouped and analyzed according to the presence or absence of aPL
antibodies and preexisting SLE. The patients are followed regularly during the course of the
pregnancy, collecting medical and obstetrical information as well as serial blood specimens
for complement and cytokine assays. The data obtained will be analyzed and used to identify
mechanisms and predictors of poor fetal outcome. We expect that the insights provided through
this study will suggest means to prevent, arrest or modify these conditions.

Inclusion Criteria:

- Patient pregnant with live intrauterine pregnancy, as defined by positive test for
elevated β-HCG, but ≤ 12 weeks by gestation (for subjects without aPL antibodies) and
≤18 weeks (for subjects with aPL antibodies)

- Patient between the ages of 18-45 and able to give informed consent, or age < 18 years
with parental consent

- Hematocrit > 26%

- For APL positive:

- aCL: IgG >= 40 GPL units; IgM >= 40 MPL units

- Positive LAC (RVVT, Kaolin, dilute TTI or PTT LA)

- Anti-β2GPI: IgG >= 40 GPL units; IgM >= 40 MPL units

- For control subjects:

- At least one successful pregnancy

- No history of fetal death (death of conceptus ≥ 10 weeks' gestation)

- No more than 1 miscarriage < 10 weeks' gestation

- No history of positive aPL in local lab or positive aPL in core labs at screening

- Not currently a smoker

- No medical problems requiring chronic treatment

Exclusion Criteria:

- Diabetes mellitus (Type I and Type II) antedating pregnancy

- Known or suspected hereditary complement deficiency (defined by CH50 = 0)
We found this trial at
9
sites
535 E 70th St
New York, New York 10021
(212) 606-1000
Principal Investigator: Michael D. Lockshin, M.D.
Phone: 212-774-7361
Hospital for Special Surgery Founded in 1863, Hospital for Special Surgery is the nation
?
mi
from
New York, NY
Click here to add this to my saved trials
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Jill P. Buyon, M.D.
Phone: 212-774-7361
?
mi
from
New York, NY
Click here to add this to my saved trials
630 W 168th St
New York, New York
212-305-2862
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73104
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Salt Lake City, Utah 84132
Principal Investigator: Ware Branch, M.D.
Phone: 801-585-7617
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Toronto, Ontario
Principal Investigator: Carl Laskin, M.D.
Phone: 416-506-9203
?
mi
from
Toronto,
Click here to add this to my saved trials